Stifel on Intellia Therapeutics (NTLA): 'Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach'
Tweet Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Buy rating and $80.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
